The Workshop Programme 2022

We are already working intensely on the Workshop Programme 2022 and will publish first details by end of September 2021.

 

We are hoping to welcome you at Marbach in May of 2022!

The Workshop Organizers:

Robert Hermann, MD, FCP

Amin Rostami-Hodjegan, PhD, FCP

Ping Zhao, PhD

 


 

Workshop Programme 2022

Coming soon …

Afternoon Individual Arrival & Check-in at Marbach Castle
03:00 p.m. Registration & Coffee
04:00 p.m. Come Together Activities
07:30 p.m. Come Together Dinner
09:00 p.m. Live Music – TBD
08:00 – 08:30 a.m. Registration & Coffee
08:30 – 08:50 a.m. Welcome Address and Introduction into the Workshop
Amin Rostami
08:50 – 09:25 a.m. Keynote Lecture – The Philosophy of Drug Interactions
Philip D. Hansten, PharmD, Professor Emeritus, University of Washington, USA
09:25 – 09:35 a.m. Discussion
Session I: Food-Drug Interactions & Beyond
Chair: Amin Rostami
09:35 – 10:00 a.m. Gut Feeling – Proteomics of Gut Wall and Relevance to Drug Absorption and Interactions
Stefan Oswald, PhD, University of Greifswald, Germany
10:00 – 10:10 a.m. Discussion
10:10 – 10:35 a.m. Can we Predict Formulation-Dependent Food-Drug Interactions?
Rodrigo Cristofoletti, PhD, Assistant Professor at the Center of Pharmacometrics & Systems Pharmacology, University of Florida, Gainesville, USA.
10:35 – 10:45 p.m. Discussion
10:45 – 11:10 a.m. Coffee Break
11:10 – 11:35 a.m. Food-Drug Interactions – Considerations from the IQ Working Group and Food Effect Case Studies
Tycho Heimbach, PhD, Biopharmaceutics, Sterile & Specialty Products Group, Pharmaceutical Sciences, Merck & Co., Inc., Rahway, New Jersey, USA
11:35 – 11:45 a.m. Discussion
11:45 – 12:05 p.m. Regulatory Science on Assessing Food Drug Interaction – Highlights from New FDA Guidance
Rajanikanth Madabushi, PhD, Office of Clinical Pharmacology, Center for Drug Evaluation and Research, FDA, Silver Spring, MD, USA
12:05 – 12:15 p.m. Discussion
12:15 – 01:45 p.m. Lunch
Session II: Pharmacodynamic Interactions
Chair: Robert Hermann
01:45 – 02:10 p.m. Common Pharmacodynamic Interactions of Clinical Importance
David Juurlink; MD, PhD, FRCPC, Sunnybrook Health Sciences Centre, Toronto, Ontario, Canada
02:10 – 02:20 p.m. Discussion
02:20 – 02:45 p.m. Revisiting Pharmacodynamic Interactions: Benefits and Watch-outs in Oncology
Jin Yan Jin, PhD, Genentech, San Francisco, California, USA
02:45 – 02:55 p.m. Discussion
02:55 – 03:20 p.m. Coffee Break
Session III: The Final FDA Guidance Documents on Drug Interactions
Chair: Amin Rostami
03:20 – 03:45 p.m. Introductory Lecture: What did the FDA Change when it Finalized its In Vitro Drug Interaction Guidance in January, 2020?
Andrew Parkinson, PhD, XPD Consulting, Shawnee KS, USA
03:45 – 03:55 p.m. Q & A Session with all Regulatory Attendees
03:55 – 04:20 p.m. Introductory Lecture: The Final FDA Guidance on Clinical Drug Interaction Studies — Cytochrome P450 Enzyme- and Transporter-Mediated Drug Interactions.
Robert Hermann, MD, Clinical Research Appliance, Gelnhausen, Germany
04:20– 04:40 p.m. Q & A Session with all Regulatory Attendees
07:00 p.m. Dinner
Session IV: Translational DMPK Session
Chair: Amin Rostami
08:50 – 9:00 Reflections on Day 1 and Opening Remarks Day 2
09:00 – 09:25 a.m. Liquid Biopsy, its Applications, Limitations, and Potential Role for Characterising Individual Hepatic Drug Elimination Capacity
Brahim Achour, PhD, University of Manchester, UK. Appointed Assistant Professor at the Faculty of the College of Pharmacy, University of Rhode Island (URI) (from September 2021)
09:25 – 09:35 a.m. Discussion
09:35 – 10:00 a.m. Metabolic Reaction Phenotyping: Do’s and Don’ts, and the Oscar Nomination Process (is Metabolism the Best Actor or the Best Supporting Actor?)
Andrew Parkinson, PhD, XPD Consulting, Shawnee KS, USA
10:00 – 10:10 a.m. Discussion
10:10 – 10:35 a.m. “SLC-Phenotyping”: Quantifying Contribution of Transporters to the Hepatic Uptake Clearance of Drugs
Manthena V Varma, PhD, Pfizer, Groton, CT, USA
10:35 – 10:45 a.m. Discussion
10:45 – 11:10 p.m. Coffee Break
Session V: Pediatric DDIs
Chair: Ping Zhao
11:10 – 11:35 a.m. Are Neonates and Young Infants Protected against DDIs Despite their Exposure to a Multitude of Medicines?
Johannes N. van den Anker, MD, PhD, Children’s National Hospital, University Children’s Hospital Basel, University of Basel, Switzerland
11:35 – 11:45 a.m. Discussion
11:45 – 12:10 a.m. Application of Pharmacometric Approaches and Real-World Data to Characterize Drug-Drug Interactions in Infants and Children
Daniel Gonzalez, PharmD, PhD, University of North Carolina at Chapel Hill, Chapel Hill, NC, USA
12:10 – 12:20 p.m. Discussion
12:20 –01:45 a.m. Lunch
Session VI: Herb-Drug DDIs
Chair: Ping Zhao
01:45 – 02:10 p.m. Herbal Drug-Drug Interactions. A Meta-Analysis and Novel Insights
Ingolf Cascorbi, MD, PhD, University of Kiel, Germany
02:10 – 02:20 p.m. Discussion
02:20 – 02:55 p.m. Looking Back 2 Decades: Revisiting Clinically Relevant Drug Interactions with St. John’s Wort
Veronika Butterweck, PhD, Max Zeller und Söhne, Romanshorn, Switzerland
02:55 – 03:05 p.m. Discussion
03:05 – 03:30 p.m. Translational Approaches to Untangle Herb-Drug Interactions
Mary Paine, RPh, PhD, Washington State University, Spokane, Washington, USA
03:30 – 03:40p.m. Discussion
03:40 – 04:05 p.m. Coffee Break
Session VII: Q & A Session Day 2
Chairs: Ping Zhao & Amin Rostami
04:05 – 04:25 p.m. Q & A Session Involving Sessions IV – VI
04:25 – 04:30 p.m. Concluding Remarks
End of Meeting & Departure
Last Update: 23.03.2021